Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
2
|
pubmed:dateCreated |
1993-9-28
|
pubmed:abstractText |
Two hundred and seventy patients under 71 years of age with myocardial infarction less than 4 hours old, defined by clinical and electrocardiographic criteria, were included in this trial and followed up for 1 year: two groups of 89 and 92 patients were randomised to receive APSAC (30 mg i.v. over 5 minutes) or rt-PA (10 mg bolus + 5000 IU of heparin as a bolus, followed by 90 mg rt-PA over 3 hours) and compared with a control series of 89 consecutive patients treated with streptokinase (1.5 MU in 1 hour). Heparin and aspirin (250 mg/day) were prescribed systematically. A score of efficacy was established from the following 4 parameters: patency of the infarct-related artery on coronary angiography at day 6 +/- 2 (N = 252), dyssynergic score on radiological ventriculography, infarct size on resting Thallium myocardial scintigraphy performed between day 15 and 21 (N = 242) and radionuclide ejection fraction performed at the same time. This score (0-24) was respectively 17.8 +/- 6.4 for rt-PA, 17.7 +/- 6.0 for APSAC and 18.1 +/- 6.0 for streptokinase (NS). The costs of hospital treatment were assessed by including: the cost of thrombolytic therapy (ranging from 1.7% of total cost for streptokinase to 16% for rt-PA), the cost of other treatments and biological investigations (10% of total cost); the cost of followed coronary angiography, in 33% of patients, by an angioplasty (21% of total cost), the cost of hospital stay averaging 17 days (49% of total cost in the rt-PA and APSAC groups and 56% in the streptokinase group NS).(ABSTRACT TRUNCATED AT 250 WORDS)
|
pubmed:language |
fre
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:month |
Feb
|
pubmed:issn |
0003-9683
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
86
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
209-17
|
pubmed:dateRevised |
2009-2-13
|
pubmed:meshHeading |
pubmed-meshheading:8363422-Cost-Benefit Analysis,
pubmed-meshheading:8363422-Emergencies,
pubmed-meshheading:8363422-Follow-Up Studies,
pubmed-meshheading:8363422-Humans,
pubmed-meshheading:8363422-Myocardial Infarction,
pubmed-meshheading:8363422-Plasminogen Activators,
pubmed-meshheading:8363422-Streptokinase,
pubmed-meshheading:8363422-Thrombolytic Therapy,
pubmed-meshheading:8363422-Time Factors
|
pubmed:year |
1993
|
pubmed:articleTitle |
[Myocardial infarction treated within 4 hrs: comparison of the cost-benefit ratio of 3 thrombolytic treatments: APSAC, rt-PA and streptokinase in 270 patients].
|
pubmed:affiliation |
Clinique cardiologique, CHU, Grenoble.
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Comparative Study,
English Abstract,
Randomized Controlled Trial,
Review,
Research Support, Non-U.S. Gov't,
Multicenter Study
|